AbbVie

Roche and Ypsomed Stay Top in Swiss Reputation Ranking

Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method to evaluate media reputation for 40 pharma and medtech companies. The study measured presence (coverage and reach) and tonality (positive/negative reporting) and calculated a Reputation Score (0–100) for each company across six reputation dimensions. In Pharma & Biopharma, Roche ranks first (ahead of MSD, Novartis, Sandoz and AstraZeneca). In MedTech & Diagnostics, Ypsomed remains first (ahead of Medacta, Straumann Group, Alcon and Sonova). The study notes products/services, innovation and economic performance tended to improve media reputation, while workplace issues (layoffs, relocations) and ESG/legal problems harmed reputation. The article was published on 2026-08-13.

AI Brain Fry Is Real and Unsustainable

Guest author Akash Pathak argues that widespread AI use in knowledge work is producing cognitive exhaustion—an effect dubbed “AI brain fry”—because humans lack time to experiment and remain fully in the loop. Citing recent media coverage, a Stanford study and company examples, Pathak recommends organizations carve out dedicated time for tinkering with AI, invest in human-in-the-loop integration, and build AI on their own data and processes. The piece references examples including HBR coverage, India’s expansion of AI data-labeling work, reported morale issues at Meta, and product examples from Apple and Spotify. Pathak is Founder and Principal of AP Growth Consulting and wrote the essay for Marketecture on 2026-08-03.

Jefferies Recommends Quality, Low‑Stress Stocks for Summer

Jefferies published an analyst note advising investors to own high‑quality, low‑momentum ("low‑stress") stocks to weather increased market volatility driven by debate over tech companies' AI spending. The firm highlighted that the S&P 500 momentum index has outperformed the broader market by more than 70% since 2024 and warned that AI‑led momentum could unwind on adverse sentiment. Jefferies screened for companies with market caps above $10 billion, high quality scores, free cash flow yields above 3%, limited momentum, and valuations under 20x forward earnings. The bank provided a list of ten recommended stocks including AbbVie, American Express, Home Depot, Lowe’s, McDonald’s, Netflix, PepsiCo, Procter & Gamble, S&P Global and Stryker. The article also notes AbbVie’s recent $10.9 billion agreement to buy Apogee Therapeutics and Netflix’s scheduled Q2 results on July 16, 2026.